FoxO feedback control of basal IRS-2 expression in pancreatic β-cells is distinct from that in hepatocytes

S Tsunekawa, D Demozay, I Briaud, J McCuaig… - Diabetes, 2011 - Am Diabetes Assoc
S Tsunekawa, D Demozay, I Briaud, J McCuaig, D Accili, R Stein, CJ Rhodes
Diabetes, 2011Am Diabetes Assoc
OBJECTIVE Appropriate regulation of insulin receptor substrate 2 (IRS-2) expression in
pancreatic β-cells is essential to adequately compensate for insulin resistance. In liver, basal
IRS-2 expression is controlled via a temporal negative feedback of sterol regulatory element–
binding protein 1 (SREBP-1) to antagonize transcription factors forkhead box class O (FoxO)
1/FoxO3a at an insulin response element (IRE) on the IRS-2 promoter. The purpose of the
study was to examine if a similar mechanism controlled IRS-2 expression in β-cells …
OBJECTIVE
Appropriate regulation of insulin receptor substrate 2 (IRS-2) expression in pancreatic β-cells is essential to adequately compensate for insulin resistance. In liver, basal IRS-2 expression is controlled via a temporal negative feedback of sterol regulatory element–binding protein 1 (SREBP-1) to antagonize transcription factors forkhead box class O (FoxO)1/FoxO3a at an insulin response element (IRE) on the IRS-2 promoter. The purpose of the study was to examine if a similar mechanism controlled IRS-2 expression in β-cells.
RESEARCH DESIGN AND METHODS
IRS-2 mRNA and protein expression, as well as IRS-2 gene promoter activity, were examined in isolated rat islets. Specific transcription factor association with the IRE on the IRS-2 promoter was examined by chromatin immunoprecipitation (ChIP) assay, and their nuclear translocation was examined by immunofluorescence. A direct in vivo effect of insulin on control of IRS-2 expression in liver and pancreatic islets was also investigated.
RESULTS
In IRS-2 promoter-reporter assays conducted in isolated islets, removal of the IRE decreased basal IRS-2 promoter activity in β-cells up to 80%. Activation of IRS signaling in isolated rat islets by insulin/IGF-I (used as an experimental in vitro tool) or downstream constitutive activation of protein kinase B (PKB) significantly decreased IRS-2 expression. In contrast, inhibition of phosphatidylinositol 3-kinase (PI3K) or PKB significantly increased IRS-2 levels in β-cells. ChIP assays indicated that transcription factors FoxO1 and FoxO3a associated with the IRE on the IRS-2 promoter in β-cells in a PI3K/PKB–dependent manner, whereas others, such as SREBP-1, the transcription factor binding to immunoglobulin heavy chain enhancer 3′, and the aryl hydrocarbon receptor nuclear translocator (ARNT), did not. However, only FoxO3a, not FoxO1, was capable of driving IRS-2 promoter activity via the IRE in β-cells. In vivo studies showed insulin was able to suppress IRS-2 expression via activation of SREBP-1 in the liver, but this mechanism was not apparent in pancreatic islets from the same animal.
CONCLUSIONS
The molecular mechanism for feedback control of IRS signaling to decrease IRS-2 expression in liver and β-cells is quite distinct, with a predominant role played by FoxO3a in β-cells.
Am Diabetes Assoc